Table 2 Predictive value of endocan in various medical conditions
From: The predictive value of endocan as a novel biomarker: an umbrella study on meta-analyses
Variable | Predictive value with 95% CI interval | heterogeneity | P value of Begg’s Publication bias | P value of Egger’s publication bias | Power |
|---|---|---|---|---|---|
Diabetes mellitus | SMD 1.00, 95% CI 0.81–1.19, P < 0.01 | 62.19% | 0.24 | 0.60 | 1-b = 1 |
Overall survival of Cancers | HR: 2.48, 95% CI: 2.12–2.90, P < 0.01 | 25.80% | Not reported | 0.46 | –––– |
Recurrence-free survival of cancers | HR: 2.08, 95% CI: 1.40–3.09, P < 0.01 | 0.00% | Not reported | 0.37 | –––– |
Hypertension | SMD: 0.91, 95% CI: 0.44–1.38, P < 0.01 | 95.43% | 0.49 | 0.02 | 1-b = 1 |
Preeclampsia | SMD: 0.37, 95% CI: 0.13–0.62, P < 0.01 | 65.00% | Not reported | 0.41 | 1-b = 0.99 |
Coronary artery disease | SMD: 0.99, 95% CI: 0.58–1.39, P < 0.01 | 89.8% | 0.36 | Not reported | 1-b = 1 |
Coronary slow flow | SMD: 0.62, 95% CI: 0.45–0.78, P < 0.01 | 0.00% | 0.66 | Not reported | 1-b = 1 |
Obstructive sleep apnea | SMD: 1.30, 95% CI: 1.06–1.54, P < 0.01 | 81.3% | Not reported | 0.07 | 1-b = 1 |
Sepsis mortality | OR: 9.53, 95% CI: 3.34–27.3, P < 0.01 | 78.00% | Not reported | Not reported | 1-b = 1 |
Sepsis multiple organ dysfunction syndrome | OR: 8.33, 95% CI: 2.07–33.58, P < 0.01 | 83.00% | Not reported | Not reported | 1-b = 1 |
Sepsis respiratory failure | OR: 9.66, 95% CI: 2.26–43.95, P < 0.01 | 73.00% | Not reported | Not reported | 1-b = 1 |
Chronic kidney disease | SMD: 1.34, 95%CI: 0.20–2.48, P < 0.01 | 98.32% | Not reported | Not reported | 1-b = 1 |
COVID-19 | SMD: 1.40, 95% CI: 0.21–2.58, P = 0.02 | 95.00% | Not reported |  > 0.05 | 1-b = 1 |
Acute respiratory distress syndrome | SMD: 0.47, 95% CI: 0.10–0.84, P = 0.01 |  | Not reported | Not reported | 1-b = 0.90 |